Last 48 quarters of trend data · Healthcare · Life Science Tools
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 36.39 | 36.37 | 27.41 | 26.71 | 27.80 | 27.18 | 23.85 | 31.42 | 27.21 | 36.23 | 34.22 | 41.99 | 31.59 | 28.63 | 37.16 | 43.40 | 34.33 | 33.54 | 32.48 | 26.40 | 40.00 |
| — | +33.8% | +14.9% | -15.0% | +2.2% | -25.0% | -30.3% | -25.2% | -13.9% | +26.5% | -7.9% | -3.2% | -8.0% | -14.7% | +14.4% | +64.4% | -14.2% | +12.2% | +16.7% | +36.1% | +114.4% | |
| P/S Ratio | 5.45 | 5.16 | 3.97 | 4.01 | 4.47 | 3.94 | 3.55 | 4.57 | 4.37 | 5.57 | 5.02 | 5.39 | 4.73 | 4.64 | 4.74 | 5.22 | 4.73 | 4.69 | 4.92 | 4.95 | 6.20 |
| — | +30.8% | +11.6% | -12.3% | +2.3% | -29.1% | -29.2% | -15.2% | -7.6% | +19.9% | +6.1% | +3.3% | +0.1% | -1.0% | -3.8% | +5.5% | -23.8% | -23.0% | -10.2% | +8.3% | +40.5% | |
| P/B Ratio | 4.89 | 4.57 | 3.61 | 3.39 | 4.08 | 3.43 | 3.05 | 3.83 | 4.01 | 4.81 | 4.46 | 4.89 | 4.40 | 4.32 | 4.61 | 5.27 | 4.90 | 4.58 | 5.09 | 5.69 | 6.48 |
| — | +33.3% | +18.5% | -11.5% | +1.7% | -28.6% | -31.6% | -21.7% | -8.8% | +11.2% | -3.3% | -7.2% | -10.3% | -5.7% | -9.4% | -7.4% | -24.4% | -22.0% | -7.8% | +10.1% | +20.1% | |
| P/FCF | 33.99 | 29.63 | 28.41 | 54.09 | 18.25 | 23.91 | 34.92 | 131.27 | 17.73 | 31.14 | 31.92 | 61.72 | 15.52 | 23.58 | 40.29 | 206.30 | 18.42 | 36.03 | 52.84 | 37.45 | 35.75 |
| — | +23.9% | -18.6% | -58.8% | +3.0% | -23.2% | +9.4% | +112.7% | +14.2% | +32.1% | -20.8% | -70.1% | -15.8% | -34.6% | -23.7% | +450.9% | -48.5% | +34.8% | +75.4% | +11.6% | +111.3% | |
| EV / EBITDA | 26.07 | 28.58 | 19.70 | 20.82 | 20.46 | 19.11 | 17.77 | 21.57 | 18.94 | 25.09 | 23.56 | 24.77 | 20.70 | 19.94 | 22.13 | 24.91 | 21.53 | 21.83 | 22.00 | 17.86 | 22.12 |
| — | +49.5% | +10.8% | -3.5% | +8.0% | -23.8% | -24.6% | -12.9% | -8.5% | +25.8% | +6.5% | -0.6% | -3.9% | -8.6% | +0.6% | +39.5% | -2.7% | +9.6% | +19.1% | +36.0% | +66.6% | |
| EV / EBIT | 35.48 | 28.58 | 27.41 | 28.79 | 24.92 | 24.07 | 21.89 | 28.55 | 24.51 | 30.77 | 27.45 | 32.46 | 26.82 | 26.13 | 33.21 | 38.39 | 29.81 | 31.93 | 29.59 | 24.71 | 36.75 |
| — | +18.7% | +25.2% | +0.8% | +1.7% | -21.8% | -20.3% | -12.0% | -8.6% | +17.8% | -17.4% | -15.5% | -10.0% | -18.2% | +12.3% | +55.4% | -18.9% | +24.0% | +19.4% | +46.5% | +125.1% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 40.9% | 42.8% | 41.2% | 40.7% | 41.0% | 41.2% | 40.6% | 41.0% | 39.2% | 41.0% | 41.2% | 40.8% | 36.3% | 41.0% | 39.9% | 39.1% | 36.3% | 40.5% | 41.8% | 46.4% | 46.1% |
| — | +3.8% | +1.5% | -0.7% | +4.6% | +0.6% | -1.5% | +0.5% | +8.0% | +0.0% | +3.2% | +4.3% | +0.0% | +1.2% | -4.4% | -15.8% | -21.2% | -18.7% | -14.5% | -11.7% | -8.1% | |
| Operating Margin | 18.2% | 18.6% | 17.4% | 16.9% | 18.8% | 18.7% | 17.7% | 17.8% | 19.9% | 18.1% | 16.7% | 16.6% | 18.3% | 18.7% | 16.7% | 15.9% | 17.3% | 16.5% | 17.7% | 24.0% | 25.0% |
| — | -0.1% | -1.5% | -4.6% | -5.3% | +3.2% | +5.9% | +6.8% | +8.8% | -3.2% | +0.1% | +4.5% | +5.5% | +13.4% | -5.8% | -33.8% | -30.7% | -34.6% | -27.1% | -22.5% | -15.8% | |
| Net Margin | 15.1% | 14.2% | 14.5% | 15.0% | 16.2% | 14.5% | 14.9% | 14.5% | 16.1% | 15.4% | 14.7% | 12.8% | 15.0% | 16.2% | 12.7% | 12.0% | 13.8% | 14.0% | 15.2% | 18.7% | 15.5% |
| — | -2.4% | -2.8% | +3.2% | +0.7% | -5.5% | +1.4% | +13.3% | +7.3% | -5.2% | +15.3% | +6.7% | +8.8% | +15.8% | -16.0% | -35.8% | -11.2% | -31.3% | -23.1% | -20.6% | -34.6% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 13.1% | 3.2% | 3.3% | 3.1% | 3.8% | 3.2% | 3.2% | 3.0% | 3.7% | 3.4% | 3.3% | 2.9% | 3.5% | 3.8% | 3.2% | 3.0% | 3.6% | 3.5% | 4.0% | 5.4% | 4.2% |
| — | +0.9% | +2.6% | +2.9% | +1.8% | -5.9% | -2.8% | +5.8% | +4.9% | -12.1% | +5.4% | -3.5% | -1.5% | +10.6% | -20.8% | -44.8% | -13.8% | -31.1% | -21.7% | -19.7% | -44.7% | |
| ROA | 6.5% | 1.5% | 1.5% | 1.5% | 1.9% | 1.6% | 1.6% | 1.5% | 1.9% | 1.6% | 1.6% | 1.4% | 1.7% | 1.8% | 1.4% | 1.3% | 1.7% | 1.7% | 1.8% | 2.4% | 2.0% |
| — | -4.3% | -5.1% | -3.8% | -0.0% | -3.5% | +2.0% | +13.2% | +11.2% | -8.6% | +9.8% | +0.9% | -0.9% | +8.7% | -20.6% | -43.0% | -14.6% | -38.7% | -33.6% | -31.9% | -47.6% | |
| ROIC | 7.5% | 1.9% | 1.7% | 1.6% | 2.1% | 1.9% | 1.8% | 1.7% | 2.2% | 1.8% | 1.7% | 1.7% | 2.0% | 2.0% | 1.8% | 1.8% | 2.1% | 1.9% | 2.0% | 3.0% | 3.3% |
| — | -0.4% | -4.4% | -8.6% | -4.4% | +1.5% | +2.8% | +2.2% | +7.9% | -6.8% | -3.0% | -2.4% | -5.1% | +5.9% | -12.3% | -40.6% | -36.6% | -48.5% | -41.5% | -39.3% | -35.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.74 | 0.76 | 0.81 | 0.83 | 0.74 | 0.70 | 0.70 | 0.69 | 0.66 | 0.72 | 0.74 | 0.78 | 0.78 | 0.78 | 0.77 | 0.83 | 0.82 | 0.67 | 0.71 | 0.81 | 0.89 |
| — | +8.3% | +16.0% | +20.0% | +11.5% | -3.0% | -6.5% | -11.5% | -15.1% | -7.3% | -3.8% | -6.1% | -4.8% | +16.4% | +8.7% | +2.8% | -7.9% | +18.9% | +39.8% | +52.0% | +35.8% | |
| Debt / EBITDA | 3.62 | 16.51 | 14.65 | 16.61 | 13.00 | 13.04 | 13.54 | 13.43 | 10.89 | 13.30 | 13.90 | 13.93 | 12.87 | 12.48 | 12.90 | 13.76 | 12.73 | 11.24 | 10.90 | 8.99 | 10.81 |
| — | +26.6% | +8.2% | +23.6% | +19.4% | -1.9% | -2.6% | -3.6% | -15.4% | +6.5% | +7.7% | +1.3% | +1.1% | +11.1% | +18.4% | +53.1% | +17.8% | +54.1% | +68.9% | +78.1% | +79.2% | |
| Current Ratio | 1.89 | 1.81 | 1.55 | 1.53 | 1.89 | 1.50 | 1.93 | 1.77 | 1.66 | 1.63 | 1.72 | 1.70 | 1.75 | 1.63 | 1.42 | 1.27 | 1.48 | 1.74 | 1.65 | 1.56 | 1.50 |
| — | +20.7% | -19.8% | -14.0% | +13.8% | -8.1% | +12.1% | +4.6% | -5.4% | -0.1% | +21.7% | +33.3% | +18.3% | -6.0% | -13.9% | -18.2% | -0.9% | -45.6% | -40.8% | -38.5% | -29.8% | |
| Quick Ratio | 1.53 | 1.41 | 1.18 | 1.15 | 1.53 | 1.11 | 1.50 | 1.38 | 1.29 | 1.26 | 1.37 | 1.33 | 1.39 | 1.25 | 1.02 | 0.92 | 1.15 | 1.22 | 1.13 | 1.10 | 1.12 |
| — | +26.8% | -21.3% | -16.5% | +19.1% | -11.6% | +9.0% | +3.8% | -7.5% | +0.6% | +35.1% | +45.0% | +20.8% | +2.3% | -10.1% | -16.9% | +2.8% | -52.2% | -46.5% | -42.3% | -35.6% | |
| Interest Coverage | 6.12 | 6.01 | 5.20 | 5.31 | 6.82 | 6.26 | 5.23 | 6.35 | 6.06 | 5.11 | 5.19 | 5.37 | 4.92 | 5.49 | 5.39 | 5.54 | 7.61 | 10.25 | 13.95 | 19.68 | 12.57 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Bull/bear thesis, analyst target revisions, and earnings execution.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TMO stock.
Thermo Fisher Scientific Inc.'s current P/E is 36.4x. The average P/E over the last 4 quarters is 29.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Thermo Fisher Scientific Inc.'s current operating margin is 18.2%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Thermo Fisher Scientific Inc.'s business trajectory between earnings reports.